BIO
Bio-Rad Laboratories, Inc. Healthcare - Medical Devices Investor Relations →
Bio-Rad Laboratories, Inc. (BIO) closed at $264.49 as of 2026-03-20, trading 24.2% below its 200-week moving average of $349.15. This places BIO in the extreme value zone. The stock moved further from the line this week, up from -25.0% last week. The 14-week RSI sits at 36, indicating neutral momentum.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.86 ratio) is neutral — neither side is clearly dominating.
Over the past 2355 weeks of data, BIO has crossed below its 200-week moving average 27 times. On average, these episodes lasted 23 weeks. Historically, investors who bought BIO at the start of these episodes saw an average one-year return of +6.1%.
With a market cap of $7.1 billion, BIO is a mid-cap stock. The company generates a free cash flow yield of 3.6%. Return on equity stands at 10.8%. The stock trades at 1.0x book value.
The company has been aggressively buying back shares, reducing its share count by 8.8% over the past three years.
Over the past 33.2 years, a hypothetical investment of $100 in BIO would have grown to $4470, compared to $2683 for the S&P 500. That represents an annualized return of 12.1% vs 10.4% for the index — confirming BIO as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 67.2% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: BIO vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After BIO Crosses Below the Line?
Across 19 historical episodes, buying BIO when it crossed below its 200-week moving average produced an average return of +11.5% after 12 months (median +14.0%), compared to +15.6% for the S&P 500 over the same periods. 59% of those episodes were profitable after one year. After 24 months, the average return was +64.9% vs +33.7% for the index.
Each line shows $100 invested at the moment BIO crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
BIO has crossed below its 200-week MA 27 times with an average 1-year return of +6.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jun 1981 | Jun 1981 | 1 | 0.9% | -45.7% | +10971.7% |
| Jul 1981 | Jul 1981 | 1 | 1.0% | -52.7% | +10971.7% |
| Aug 1981 | Feb 1983 | 81 | 57.3% | -59.7% | +10971.7% |
| Nov 1987 | Dec 1987 | 5 | 21.0% | +33.3% | +5777.6% |
| Jan 1988 | Feb 1988 | 1 | 0.7% | +22.0% | +5279.5% |
| Dec 1988 | Mar 1989 | 15 | 8.0% | -12.7% | +4370.3% |
| May 1989 | May 1990 | 53 | 24.6% | +4.8% | +4277.8% |
| Jul 1990 | Feb 1991 | 27 | 34.8% | +5.9% | +4076.2% |
| Sep 1991 | Sep 1991 | 1 | 0.7% | +2.7% | +4218.2% |
| Oct 1991 | Dec 1991 | 10 | 5.2% | -7.5% | +4218.2% |
| Feb 1992 | May 1992 | 11 | 9.5% | -10.7% | +4131.8% |
| Jun 1992 | Jun 1992 | 2 | 1.6% | -23.1% | +4218.2% |
| Sep 1992 | Apr 1994 | 84 | 44.3% | -23.0% | +4189.0% |
| May 1994 | May 1994 | 1 | 1.1% | +94.2% | +4533.4% |
| May 1994 | Jun 1994 | 1 | 1.0% | +83.2% | +4533.4% |
| Feb 1998 | Feb 1998 | 3 | 5.0% | -14.0% | +2092.7% |
| Aug 1998 | Apr 1999 | 35 | 28.3% | +8.0% | +2005.4% |
| Jul 1999 | Feb 2000 | 32 | 18.0% | -8.0% | +1896.2% |
| Apr 2000 | Oct 2000 | 28 | 18.3% | +33.3% | +1929.7% |
| Nov 2008 | Jul 2009 | 38 | 26.9% | +39.0% | +277.8% |
| Aug 2010 | Aug 2010 | 1 | 2.5% | +19.5% | +219.7% |
| Sep 2011 | Oct 2011 | 3 | 2.1% | +19.4% | +193.3% |
| Nov 2011 | Dec 2011 | 3 | 2.1% | +15.5% | +193.8% |
| Oct 2014 | Oct 2014 | 2 | 3.2% | +28.0% | +143.3% |
| Nov 2014 | Nov 2014 | 2 | 1.6% | +26.9% | +139.1% |
| Jun 2022 | Jun 2022 | 1 | 3.0% | -18.8% | -43.0% |
| Aug 2022 | Ongoing | 186+ | 49.6% | Ongoing | -44.7% |
| Average | 23 | — | +6.1% | — |
Frequently Asked Questions
Is BIO below its 200-week moving average?
Yes. As of 2026-03-20, Bio-Rad Laboratories, Inc. (BIO) is trading 24.2% below its 200-week moving average of $349.15. The current price is $264.49.
What is BIO's 200-week moving average price?
Bio-Rad Laboratories, Inc.'s 200-week moving average is $349.15 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when BIO drops below its 200-week moving average?
BIO has crossed below its 200-week moving average 27 times in our data. On average, buying at that moment produced a one-year return of +6.1%. These dips have historically been decent entry points. These episodes lasted 23 weeks on average.
Is BIO a good value right now?
Here's what our data says about BIO as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 36. Free cash flow yield is 3.6%. Return on equity is 10.8%. Price-to-book is 1.0x. This is not a buy or sell recommendation — always do your own research.
How does BIO compare to the S&P 500?
Over the past 33.2 years, $100 invested in BIO would have grown to $4470, compared to $2683 for the S&P 500. That's 12.1% annualized vs 10.4% for the index. BIO has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20